

7. Referenties

- Albert 2011 Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ et al. Azithromycin for prevention of exacerbations COPD. *N Eng J Med* 2011; 365: 689-98.
- Alsaeedi 2002 Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. *Am J Med* 2002;113:59-65.
- Appleton 2006 Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. *Cochran Database Syst Rev.* 2006 Jul19;3:CD001104.
- Baan 2012 Baan D, Heijmans M, Spreeuwenberg P, Rijken M. Zelfmanagement, vanuit het perspectief van mensen met astma of COPD. Nivel 2012. ISBN: 978-94-6122-128-5. www.nivel.nl
- Barr 2006 Barr RG, Bourbeau J, Camargo CA, Ram FSF. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. *Thorax.* 2006;61:854-62.
- Bartoli 2009 Bartoli L, Zanaboni P, Masella C, Ursini N. Systematic review of telemedicine services for patients affected by Chronic Obstructive Pulmonary Disease. *Telemedicine and e-health* 2009. Vol 15, No.9 : 877-883.
- Basheti 2007 Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. *J Allergy Clin Immunol* 2007 Jun;119(6):1537-8.
- Beeh 2012 Beeh KM, Singh D, Scala DL, Drollman A. Once-daily NVA237 improves exercise tolerance from the First dose in patients with COPD: the GLOW3 trial. *Int J Chron Obstruct Pulmon Dis* 2012; 7: 503-513.
- Bestall 1999 Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999;54:581-6.
- Black 2003 Black P, Staykova T, Chacko E, Ram FS, Poole Prophylactic antibiotic therapy for chronic bronchitis (Cochrane review). In the Cochrane Library, issue 4, 2003.
- Bolton 2011 Bolton CE, Waters CS, Peirce S, Elwyn G. Insufficient evidence of benefit: a systematic review of home telemonitoring for COPD. *J of evaluation in Clinical Practice* 2011; 17: 1216-1222.
- Breekveldt 2007 Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. *Respir Med.* 2007 Jul;101(7):1398-405.
- Broeders 2009 Broeders ME, Sanchis J, Levy ML, Crompton GK, Dekhuijzen PN; ADMIT Working Group. The ADMIT series issues in inhalation therapy.2. Improving technique and clinical effectiveness. *Prim Care Respir J.* 2009 Jun;18(2):76-82.
- Burge 2000 Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ* 2000;320:1297-303.
- Calverley 2003 Calverley PM, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A et al. TRial of Inhaled Steroids And long-acting beta2 agonists study group (TRISTAN). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 2003;361:449-56.
- Calverley 2007 Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007;176:154-161.

- Calverley 2009 Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet* 2009;374:685-694.
- Castillo 2009 Castillo D, Guayta R, Giner J, Burgos F, Capdevila C, Soriano JB et al. COPD case finding by spirometry in high-risk customers of urban community pharmacies: A pilot study. *Respir Med* 2009;103:839-845.
- CBO 2000 Richtlijn zuurstof behandeling thuis, Kwaliteitsinstituut voor de Gezondheidszorg CBO 2000
- CBO 2003 Richtlijn Het gebruik van vernevelapparaten in de thuissituatie: indicatiestelling, zorgproces, hulpmiddelen en organisatie. Kwaliteitsinstituut voor de Gezondheidszorg CBO 2003.
- CBO 2009 CBO richtlijn Palliatieve zorg voor mensen met COPD (concepttekst 2009).
- CBO 2010 Richtlijn Diagnostiek en behandeling van COPD. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Actualisatie maart 2010.
- CBO 2011 CBO richtlijn osteoporose en fractuurpreventie, derde herziening, 2011.
- CBS 1999 Centraal Bureau voor Statistiek (CBS). Enquete Beroepsbevolking 1999 (EBB). Den Haag: SDU/Uitgeverij, 2000.
- Chavannes 2005 Chavannes N, Schermer T, Wouters E, Folgering H, Akkermans R, Metsemakers J, Weel C van, Schayck O van. Demographic and clinical determinants of response to N-acetylcysteine versus fluticasone in mild to moderate COPD in primary care: The COOPT Study. *Eur Respir J* 2005; 26 (S49): 1356.
- Chrystyn 2003 Chrystyn H. Is inhalation rate important for dry powder inhalers ? Using the In-Check Dial to identify these rates. *Respir Med* 2003 ; 97 :181-187.
- Costello 2011 Costello MJ, Sproule B, Victor JC, Leatherdale ST, Zawertailo L, Selby P. Effectiveness of pharmacist counseling combined with nicotine replacement therapy: a pragmatic randomized trial with 6,987 smokers. *Cancer Causes Control*. 2011 Feb;22(2):167-80
- Combivent 1994 COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agents alone. An 8day multicenter trial. *Chest* 1994;105(4):14119.
- Dahl 2001 Dahl R, Greefhorst LA, Nowak D, Noikov V, Byrne AM, Thomsom MH et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;164:778-84.
- Dahl 2010 Dahl R, Chung KF, MAGnussen H, Nonikov V, Jack D, Bleasdale P et al; INVOLVE. Efficacy of a new once-daily long-acting inhaled beta-agonist indacaterol versus twice-daily formoterol in COPD. *Thorax* 2010;65:473-9.
- De Boer 2009 De Boer A., Ruijgrok L. Luchtwegen. In Bouwman-Boer Y, Le Brun PPH, Oussoren C et al. Recepteerkunde. Productzorg en bereiding van geneesmiddelen. Houten: Bohn Stafleu van Loghum, 2009:625-661.
- Dekhuijzen 1998 Dekhuijzen PNR. Inhalatiemedicatie bij volwassenen met obstructieve longaandoeningen: poeder of aerosol? *NTVG* 1998;142:1369-74.
- Dekhuijzen 2013a Dekhuijzen PNR, van Helvoort HAC, Willems LM, Heijdra YF. Stand van zaken. Medicamenteuze interventie bij COPD: ook bij patienten met lichte en matige COPD? *NTVG* 2013; 157: A5399.
- Dekhuijzen 2013b Dekhuijzen PNR, Vincken W, Virchow JC, Roche N, Agusti A, et al. "Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach." *Respir Med* 2013 doi: 10.1016/j.rmed.2013.09.013.
- Dent 2007 Dent LA, Harris KJ, Noonan CW. Tobacco interventions delivered by pharmacists: a summary and systematic review. *Pharmacotherapy* 2007 Jul;27(7):1040-51.
- Dicpinigaitis 2006 Dicpinigaitis P. Angiotensin-Converting Enzyme Evidence-Based Clinical Practice Guidelines Inhibitor-Induced Cough : ACCP Chest 2006;129;169S-173S

- Dolovich 2005 Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines. American College of Chest Physicians/American College of Asthma, Allergy and Immunology. Chest 2005;127:335-71.
- Donohue 2002 Donohue JF, Noord JA van, Bateman ED, Langley SJ, Lee A, Witek TJ et al. A 6-month, placebocontrolled study comparing lung function and health status changes in COPD patients treated with tiotropium of salmeterol. Chest 2002;122:47-55.
- Evers 1992 Evers NAEM, Baas AAF, van der Meer C. Hoest als bijwerking van angiotensine- 'converting'-enzym-remmers, Ned Tijdschr Geneeskd. 1992;136:1856-8
- Fabbri 2009 Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised controlled trials. Lancet 2009;374:695-703.
- Ferrer 1997 Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC et al. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med 1997;127:1072-9.
- Franek 2012 Franek J. Home telehealth for patients with Chronic Obstructive Pulmonary Disease (COPD): an Evidence Based Analysis. Ontario Health Technology Assessment Series. March 2012; Vol 12: No. 11, 1-58.
- Gallefoss 2004 Gallefoss F. The effects of patients education in COPD in a 1-year follow-up randomised, controlled trial. Patient Educ Couns 2004;52(3):259-66.
- Gartlehner 2006 Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006;253-62.
- Gebu 2013 Roflumilast en suïcidaliteit (Let op!). Geneesmiddel bulletin 2013;47(6):71-2.
- GLI 2012 Global Lung Function Initiative. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43.
- GOLD 2010 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2010.
- GOLD 2013 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease. Updated 2013 (www.goldcopd.org)
- GVS 2014 GVS rapport olodaterol 7 februari 2014
- Hammerlein 2011 Hammerlein A, Muller U, Schulz M. Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients. J Eval Clin Pract. 2011;17(1):61-70
- Halpern 2004 Halpern MT, Schmier JK, Van Kerkhove MD, Watkins M, Kalberg CJ. Impact of longterm inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. Ann Allergy Asthma Immunol 2004;92:201-7.
- Health Base 2011 Geneesmiddelen, Zwangerschap en Borstvoeding. Health Base / TIS Lareb, Houten, januari 2011.
- Health Base 2013 Commentaren Medicatiebewaking 2012-2013. Health Base, Houten, 2013.
- Heijmans 2013 Heijmans M, Zwijnenburg N, Baan D, Spreeuwenberg P, Deville W. Monitor zorg-en leefsituatie van mensen met astma of COPD – Trends en ontwikkelingen over de periode van 2011-2012. Nationaal panel Chronisch Zieken en Gehandicapten. Nivel 2013. ISBN:978-94-6122-199-5. www.nivel.nl
- Hochrainer 2005 Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005; 18(3); 273-282.

- Hogg 2009 Hogg W, Lemelin J, Dahrouge S, Liddy C, Armstrong CD, Legault F, Dalziel B, Zhang W. Randomized controlled trial of anticipatory and preventive multidisciplinary team care: for complex patients in a community-based primary care setting. *Can Fam Physician*. 2009 Dec;55(12):e76-85.
- Hurst 2010 Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med*. 2010;363(12):1128-1138
- Jacobs 2004a Jacobs JE. Kwaliteit van leven bij patiënten met COPD: kunnen we deze meten en verbeteren? *Patient Care* 2004a;31:127-34
- Jacobs 2004b Jacobs JE, Maille AR, Akkermans RP, Van Weel C, Grol RP. Assessing the quality of life of adults with chronic respiratory diseases in routine primary care: construction and first validation of the 10-item Respiratory Illness Questionnaire-monitoring 10 (RIQ-MON10). *Qual Life Res* 2004b;13:1117-27.
- Jarab 2012 Jarab AS, AlQudah SG, Khmour M, Shamssain M, Mukattash TL. Impact of pharmaceutical care on health outcomes in patients with COPD. *Int J Clin Pharm* 2012; 34: 53-62.
- Jimenez-Ruiz 2001 Jimenez-Ruiz CA, Masa F, Miravittles M, Gabriel L, Viejo JL, Villasante C. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. *Chest* 2001;119(5):365-1370.
- Jones 2003 Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. *Eur Respir J* 2003;21:68-73.
- Jorgensen 2007 Jorgensen NR, Schwarz P, Holme I et al. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. *Respir Med* 2007;101: 177-185.
- Kampelmacher 2001 Kampelmacher MJ, Rooyackers JM, Lammers JWJ. CBO-richtlijn 'Zuurstofbehandeling thuis'. *Ned Tijdschr Geneesk* 2001;145(41):1975-1980
- Kanner 2001 Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. *Am J Respir Crit Care Med*. 2001;164(3):358-64.
- Katsura 2002 Katsura H, Kida K. A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. *Chest* 2002;122, 1949-1955.
- Kerwin 2012 Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VKT, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. *Eur Respir J* 2012; 40: 1106-1114.
- Khdour 2009 Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. *Br J Clin Pharmacol*. 2009 OCT;68(4):588-98.
- Khdour 2011 Khdour MR, Agus AM, Kidney JC, Smyth BM, Elnay JC, Crealy GE. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. *Int J Clin Pharm* 2011; 33: 665-673.
- KNMP 2011a FPZ-handboek Astma COPD. KNMP-kennisbank 2011.
- KNMP 2011b Zelfzorgstandaard stoppen met roken; 'Standaarden voor Zelfzorg', KNMP; zesde druk: augustus 2011, 217-234.
- KNMP 2013 G-standaard. KNMP-kennisbank oktober 2013.
- KNMP RL diabetes KNMP Richtlijn diabetes mellitus 2, 2011
- Kocks 2006 Kocks JW, Tuinenga MG, Uil SM, Van den Berg JW, Stahl E, Van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. *Respir Res* 2006;7:62.

- Kornmann 2011 Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C et al; INLIGHT-2. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. *Eur Respir J* 2011;37:273-9.
- Kremer 2003 Kremer AM. COPD and work. Hoofddorp: TNO Arbeid, 2003.
- LAN 2010 Zorgstandaard COPD, Long Alliantie Nederland. 2010.
- LAN 2011 Goed gebruik Inhalatie Medicatie Astma en COPD, Long Alliantie Nederland, dec 2011.
- LAN 2013 Zorgstandaard COPD, Long Alliantie Nederland 2013.
- Lainscak 2011 Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haeling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. *Respir Med* 2011; 105 suppl 1: S44-9.
- Lapperre 2009 Lapperre TS, Snoeck-Stroband JB, Gosman MME, et al. and the GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease) Study Group. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. *Ann Intern Med* 2009;151:517-27.
- Lee 1987 Lee BL, Benowitz NL, Jacob P. Cigarette abstinence, nicotine gum and theophylline disposition. *Ann Intern Medicine* 1987; 106:553-555.
- LESA 2007 Lakerveld-heijl K, Boomsma LJ, Geijer RMM, Gosselink R, Muris JWM, Vermeeren MAP, Van Hensbergen W, Verhoef M, Flikweert S, Van Ravensberg DC. Landelijke Eerstelijns Samenwerkings Afspraak COPD. *Huisarts Wet* 2007;50(8):S21-S27.
- Liesker 2002 Liesker JJ, Wijkstra PJ, Ten Hacken NH, Koeter GH, Postma DS, Kerstjens HA. A systematic review of the effect of bronchodilators on exercise capacity in patients with COPD. *Chest* 2002;121:597-608.
- Loke 2014 Loke YK, Singh S, Furber CD. Tiotropium and the risk of death in COPD [correspondence] *NEJM* 2014; 370:480-483
- Mahler 1999 Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. *Chest* 1999;115:957-65
- Malhotra 2007 Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. *Lancet* 2007; 369: 482-90.
- Mann 2009 Mann RP, Zaiken K. Management of chronic obstructive pulmonary disease by pharmacist in an internal medicine department. *Am J Health Syst Pharm*. 2009 May 15;66(10):890,892-3.
- McCrary 2002 McCrary DC, Brown CD. *Cochrane Database Syst Rev*. 2002;(4):CD003900, Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease.
- McIvor 2011 McIvor RA, Tunks M, Todd DC. COPD. *Clin Evid (Online)* 2011 Jun 6;2011.pii: 1502.
- McLean 2011 McLean S, Nurmatov U, Liu JL, Pagliari C, Car J, Sheikh A. Telehealthcare for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2011 Jul 6;(7):CD007718. doi: 10.1002/14651858.CD007718.pub2.
- Mehuys 2008 Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, Brusselse G. Effectiveness of pharmacist interventions for asthma control improvement. *Eur Respir J* 2008 Apr;31(4):790-9. Epub 2007 Dec 19.
- Molimard 2005 Molimard M. How to achieve good compliance and adherence with inhalation therapy. *Curr Med Res Opin*. 2005;21 Suppl 4:S33-7.
- NAN 2006 Nederlandse Apotheeknorm. KNMP 2006.
- Nannini 2007 Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews* 2007, Issue 4.

NHG 2007	NHG Standpunt Off label voorschrijven van geneesmiddelen (actualisatie 2007).
NHG Hoesten 2013	NHG-Standaard Acut Hoesten, Nederlands Huisartsen Genootschap 2013.
NHG Astma 2007	NHG-Standaard Astma voor volwassenen, Nederlands Huisartsen Genootschap 2007.
NHG COPD 2007	NHG-Standaard COPD, Nederlands Huisartsen Genootschap 2007.
NHG Fractuur 2012	NHG-standaard Fractuurpreventie, Nederlands Huisartsen Genootschap 2012.
NHG Hartfalen 2010	NHG-Standaard Hartfalen, Nederlands Huisartsen Genootschap 2010.
NHG Preventie 2013	NHG-PraktijkWijzer Het PreventieConsult Module COPD. Nederlands Huisartsen Genootschap 2013.
Nishimura 2002	Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002 May; 121(5):1434-40.
OHTAC 2012	OHTAC COPD collaborative. Chronic Obstructive Pulmonary disease (COPD) Evidentiary Framework . Ontario Health Technology Assessment series March 2012; Vol 12, No. 2: 1-97.
Pallialine 2010	Richtlijn COPD versie 1,0 2010: www.pallialine.nl/copd
Paggiaro 1998	Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-80.
Partridge 2009	Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25 (8): 2043-2048
Pharmacom 2011	Medicatie Monitoring Pharmacom. www.pharmapartners.nl/index.jsp?PAGEID=849775&IDS=582298 824608 849774 849811 &BLOCKNR=1&glid=CJmCzYKmqwCFYOFDgod8HfqPw
Polisena 2010	Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K, et al. Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta analysis. J of Telemedicine and Telecare 2010; 16:120-127.]
Poole 2006	Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst rev 2006
Ray 2012	Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. NEJM 2012; 366 (20): 1881-90.
Rennard 2001	Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1087-92.
Restrepo 2008	Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL et al. Medication adherence issues in patients treated for COPD, International Journal of COPD 2008;3(3) 371-384.
RIVM 2010	Nationaal Kompas volksgezondheid RIVM 2010, www.nationaalkompas.nl .
Rutten 2010	Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010 May 24;170(10):880-7.
Ryan 2002	Ryan AJ, Adams A, Yeager B, Farris K. Effectiveness of a pharmacist based smoking cessation program and its impact on quality of life. Pharmacotherapy 2002;22:759- 65.
Tommelein 2013	Tommelein E, Mehuys Ee, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, et al. Effectiveness of PHARMAceutical Care for Patients with COPD (PHARMACOP): a Randomized Controlled Trial. Doi: 10.1111/bcp.12242.
Schembri 2013	Schembri S, Williamson PA, Short PM, Singanayagm A, Akram A, Taylor J, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013; 346:f1235.

- Schermer 2006 Schermer TR, Saris CG, van den Bosch WJ, Chavannes NH, Van Schayck CP, Dekhuijzen PN et al. Exacerbations and associated healthcare cost in patients with COPD in general practice. *Monaldi Arch Chest Dis* 2006;65:133-40.
- Seemungal 2008 Seemungal TA, Wilkinson TM, Hurst JR, Perera WT, Sapsford RJ, Wedzicha JA, Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. *Am J Respir Crit Care Med*. 2008;178:1139-47.
- Sestini 2002 Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2002;CD001495.
- Short 2011 Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. *BMJ* 2011 May 10;342:d2549. doi: 10.1136/bmj.d2549.
- Smeele 2012 Smeele IJM, Meulepas M, Meulemans C, Reus I, Klomp MF. Eerste ervaringen met COPD-ketenzorg. *Huisarts Wet* 2012;5(55);194-8.
- Stead 2008 (CBO stoppen met roken)
- Stratelis 2004 Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. *Br J Gen Pract* 2004 Mar(500):201-6.;
- SFK 2009 SFK Data en Feiten 2009 van de Stichting Farmaceutische Kengetallen.
- SFK 2011 Webrapportage 'Praktijkondersteuning programma Astma/COPD'. www2.sfk.nl/webrapportages/ppastma
- Singh 2011 Singh S, Loke Yk, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. *BMJ* 2011 Jun 14;342:d3215.
- SPC Theolair 2011 Meda Pharma BV. Samenvatting van de productkenmerken Theolair Retard 175, 250, 350. 2011
- Stoppen met roken 2009 Zorgmodule Stoppen met roken. December 2009. www.partnershipstopmetroken.nl.
- Takemura 2011 Takemura M, Mitsui K, Itotani R, Ishitoko M, Suzuki S, Matsumoto M et al. Relationships between repeated instruction on inhalation therapy, medication adherence and health status in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2011;6:97-104.
- Ulrik 2012a Ulrik CS. Aclidinium bromide: clinical benefit in patients with moderate to severe COPD. *Open Respir Med J* 2012; 6 : 150-154.
- Ulrik 2012b Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist for Chronic Obstructive Pulmonary disease: a systematic review of clinical benefit. *Int J Chron Obstruct Pulmon Dis*. 2012; 7: 673-678.
- D'Urzo 2011 D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, et al. Efficacy and safety of once-daily NVA237 in patients with moderate- to- severe COPD: the GLOW1 trial. *Respiratory research* 2011, 12: 156.
- Van Boven 2013 Boven van JF, Chavannes NH, Molen van der T, Rutten-van Molken MPMH, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: A systematic review. *Respir Med* 2013; <http://dx.doi.org/10.1016/j.rmed.2013.8.044>.
- Van der Molen 2003 Van der Molen T, Willemse BW, Schokker S, Ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. *Health Qual Life Outcomes* 2003;1:13.
- Van der Palen 1999 Van der Palen J, Klein JJ, van Herwaarden CL, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. *Eur Respir J* 1999 Nov;14(5):1034-7.
- Van der Valk 2002 Van der Valk P, Monnickhof E, Van der Palen J, Zielhuis G, Van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. *Am J Respir Crit Care Med* 2002;166:1358-63.

- Vandevoorde 2007 Vandevoorde J, Verbanck S, Gijssels L, Schuermans D, Devroey D, De Backer J et al. Early detection of COPD: a case finding study in general practice. *Respir Med* 2007 Mar;101(3):525-30.
- Vegter 2010 Vegter S, De Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect—angiotensin-converting enzyme inhibitor induced cough. *Br J Clin Pharmacol* 2010; 69(2): 200-3
- Vestbo 2011 Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011 Sep 29; 365(13): 1184-92.
- Wise 2013 Wise AR, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium respimat inhaler and the risk of death in COPD. *NEJM* 2013; 369.
- Wouters 2005 Wouters EFM, Postma DS, Fokkens B, Hop WCJ, Prins J, Kuipers AF et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. *Thorax* 2005;60:480-487.